https://www.selleckchem.com/pr....oducts/l-monosodium-
5%, n=138) when compared to 5% (74.6%, n=138). Our analysis confirms that the implementation of new methods for detecting circulating cell-free tumor DNA in cell-free plasma is associated with poor performance. It is important to apply optimal detection methods as well as to extensively validate new methods for cell-free tumor DNA testing before treatment decisions are made. Circulating tumor DNA (ctDNA) measurements can be used to estimate tumor burden, but avoiding false-positives is a challenge. We evaluate
お気に入り
コメント
シェア
